A mixed performance in the stock price over the year has left investors with either an optimistic or pessimistic outlook, depending on their point of view. Until today this year the stock’s price performance recorded an increase of 61.81%. However, over the last six months, the performance has been weaker by 12.47%. The price of TCRX increased 14.64% over the last 30 days. And in the last five days, it has fallen by -21.63%.
TScan Therapeutics Inc. (TCRX) current stock price is $2.51. During the last trading session, the stock soared, reaching $2.6547 after opening at $2.46. The stock’s lowest point was $2.30 before it closed at $2.43.
Top 5 EV Tech Stocks to Buy for 2023
According a new report published by BloombergNEF on investment in the energy transition, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now.
Click Here to Download the FREE Report.
TScan Therapeutics Inc.’s stock has had a tumultuous market performance. The 1-year high for the company’s stock was $6.03 on 05/09/23, and the lowest price during the same period was recorded at $1.45 on 12/27/22.
52-week price history of TCRX Stock
A stock’s 52-week price history, including the low and high prices, can offer valuable insights into its current standing and future prospects. TScan Therapeutics Inc.’s current trading price is -58.41% away from its 52-week high, while its distance from the 52-week low is 72.97%. The stock’s price range over this timeframe has been between $1.45 and $6.03. The shares of the Healthcare sector company recorded a trading volume of approximately 1.55 million for the day, which was comparatively higher than the average daily volume of 1.35 million over the last three months.
The Connection Between Financial Performance and Market Capitalization
TScan Therapeutics Inc. (TCRX) has experienced a quarterly decline of -16.12% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 60.36M and boasts a workforce of 136 employees.
Expert Opinions: Analysts’ Ratings for TScan Therapeutics Inc.
As of right now, 3 analysts are rating TScan Therapeutics Inc. as a BUY, 1 of the polled analysts branded the stock as an OVERWEIGHT, 0 analyst is recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 analyst is rating the stock as SELL.
How Moving Averages and Trading Volume Data Work Together
Based on Barchart.com data, the company’s moving average over the 100-day period was 2.48, with a change in price of +0.87. Similarly, TScan Therapeutics Inc. recorded 940,902 in trading volume during the last 100 days, posting a change of +56.13%.
TCRX’s Debt-to-Equity Ratio: A Comprehensive Review
A key metric for assessing a company’s financial well-being and market status is the debt-to-equity (D/E) ratio. This ratio is derived by dividing a company’s total liabilities by its shareholders’ equity, and it demonstrates the level of debt a company uses to support its assets relative to shareholder equity. At the time of writing, the total D/E ratio for TCRX stands at 0.38. Similarly, the long-term debt-to-equity ratio is also 0.38.
TCRX Stock Stochastic Average
The raw stochastic average for TScan Therapeutics Inc. over the last 50 days is presently at 18.14%. This reflects a surge from the raw stochastic average of the previous 20 days, which was noted at 18.14%. Further, the company’s Stochastic %K and %D values for the last 20 days were 18.75% and 21.42%, respectively.